Completed Cells, Biochemistry & Physiology Genetics & Molecular Biology

The Oxford Protein Production Facility-UK

In plain English

AI plain-English summary

The Oxford Protein Production Facility will build infrastructure to churn out proteins faster than ever before, tackling a growing bottleneck in biology. DNA sequencing has exploded in speed and scale, flooding databases with the genetic blueprints for millions of unknown proteins. But knowing a protein's sequence is not the same as knowing what it does. Proteins must be physically produced and purified in the lab before scientists can study their three-dimensional shapes and functions—a slow, painstaking process that now lags far behind sequencing. This gap means that many potential drug targets, especially from human pathogens, remain unexplored. If successful, the facility will dramatically accelerate the pipeline from gene sequence to protein structure and function. This is fundamental infrastructure, not a single discovery. By enabling high-throughput protein production, it will support research across multiple scales—from atomic-level X-ray crystallography to whole-cell microscopy. The practical payoff is indirect but real: faster protein characterisation has already contributed to drugs such as the influenza treatment Zanamivir and the HIV drug Darunavir. Closing the production gap could speed similar breakthroughs for other diseases.

View original technical description
Proteins are essential components of all living cells. They comprise chains of amino acids coded for by specific DNA sequences and fold into three dimensional structures, that determine their function, for example as biological catalysts. Therefore, understanding protein structure and function is key to exploiting the information generated from sequencing of the human genome and in particular those of many human pathogens. Knowledge of individual proteins has made a major contribution to the development of a number of important drugs, e.g. Zanamivir (influenza neuraminidase inhibitor), Lapatinib (kinase inhibitor), Darunavir (HIV protease inhibitor). However, high throughput DNA sequencing continues to add to the database of known proteins at a rate that far exceeds our capacity to decipher their function. Therefore, accelerating the production of recombinant proteins is key to closing the gap between the acquisition of protein sequences and the determination of their structure and function. In response to this challenge, the Oxford Protein Production Facility will provide infrastructure to underpin the study of proteins on different length and time scales from atomic resolution (x-ray crystallography) to whole cell systems (optical microscopy).

View the original record at the funder ↗

Researchers

David Stuart (Co-Investigator)Ray Owens (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

A UK National Protein Production Facility for Biomedically Driven Structural Proteomics
A high-throughput protein expression facility for structural and cell biology
Novel fusion tags to facilitate protein production and structure determination
The Edinburgh Protein Production Facility (EPPF).
Advanced protein crystallography imaging system

Original classification

Research Grant

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.